Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Non-Current Deferred Tax Liability (2016 - 2017)

Historic Non-Current Deferred Tax Liability for Ernexa Therapeutics (ERNA) over the last 2 years, with Q4 2017 value amounting to $52000.0.

  • Ernexa Therapeutics' Non-Current Deferred Tax Liability rose 612.24% to $52000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $52000.0, marking a year-over-year increase of 612.24%. This contributed to the annual value of $52000.0 for FY2017, which is 612.24% up from last year.
  • Latest data reveals that Ernexa Therapeutics reported Non-Current Deferred Tax Liability of $52000.0 as of Q4 2017, which was up 612.24% from $49000.0 recorded in Q4 2016.
  • Ernexa Therapeutics' Non-Current Deferred Tax Liability's 5-year high stood at $52000.0 during Q4 2017, with a 5-year trough of $49000.0 in Q4 2016.